PASTIC Dspace Repository

Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in elderly Chinese patients with Alzheimer disease: A novel target for effective therapy

Show simple item record

dc.contributor.author Wang, Jianhong
dc.contributor.author Yang, Shu
dc.contributor.author Hu, Zicheng
dc.contributor.author Yang, Haimei
dc.contributor.author Wei, Dong
dc.contributor.author Wang, Duozi
dc.contributor.author Guo, Fuqiang
dc.date.accessioned 2022-12-06T05:04:52Z
dc.date.available 2022-12-06T05:04:52Z
dc.date.issued 2019-09-20
dc.identifier.citation Wang, J., Yang, S., Hu, Z., Yang, H., Wei, D., Wang, D., & Guo, F. (2019). Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in elderly Chinese patients with Alzheimer disease: A novel target for effective therapy. Pakistan Journal of Pharmaceutical Sciences, 32(SI5), 2427-2433. en_US
dc.identifier.issn 1011-601X
dc.identifier.uri http://142.54.178.187:9060/xmlui/handle/123456789/14715
dc.description.abstract This pilot study designed to evaluate the efficacy and safety of NAD+ ADP-ribosyl transferase 1 (NART) agonist in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD). In the present clinical trial, Chinese elderly patients aged ≥65 years with a confirmed diagnosis of AD were enrolled. The patients received NART agonist (test, DAG-structured PKC blockers (GF109203X)) or DNP 10mg daily (reference) for 6 months. The efficacy and safety data were collected from 120 patients (60 patients in each group) every 3 weeks until 6 months. The primary endpoints were to assess the change in cognitive score from baseline in both the treatment group. The result of the present study showed that the patients treated with DNP and NART agonist have similar efficacy and safety profile. Considering the clinical benefit, improvement in sign and symptoms of was numerically greater in DNPtreated patients as compared to NART agonist. However, a statistical difference in terms of clinical benefit was similar between both the treatment groups. Overall, both the study drugs were found comparable in relieving the symptoms of AD. This indicates that NART is a potential target for the treatment of AD in China. The results of the present study may help to design a large clinical trial to evaluate the efficacy and safety of NART agonist in comparison with DNP in AD patients en_US
dc.language.iso en en_US
dc.publisher Karachi:Pakistan Journal of Pharmaceutical Sciences, university of Karachi. en_US
dc.subject NAD+ ADP-ribosyltransferase agonist en_US
dc.subject donepezil en_US
dc.subject Alzheimer disease en_US
dc.subject Chinese elderly en_US
dc.title Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in elderly Chinese patients with Alzheimer disease: A novel target for effective therapy en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account